Heat-inactivated postbiotics derived from Lactiplantibacillus plantarum have been proposed to influence the gut–metabolic axis and thereby support weight management and metabolic health. The investigational oral formulation studied here, referred to as resM, combines heat-inactivated L. plantarum RSB11 (RSB11-HI) with vitamins (D3 and B12), chromium picolinate, white mulberry (Morus alba) leaf extract, and fenugreek (Trigonella foenum-graecum) seed extract. The study tested whether resM affects body weight and a panel of metabolic and behavioral outcomes in adults with overweight or obesity, and specifically whether it alters endogenous GLP-1 signaling.
This was a randomized, double-blind, placebo-controlled, parallel-group trial (ClinicalTrials.gov NCT06911073). Eighty adults with overweight or obesity were randomized 1:1 to receive either resM or a matched placebo for an 8-week intervention. The study was conducted in a fully remote, direct-to-consumer manner. The final scheduled weekly assessment for the primary outcome was Week 7, corresponding to completion of the 8-week intervention.
resM is an orally delivered combination therapy composed of heat-inactivated L. plantarum RSB11 (RSB11-HI) plus micronutrients and botanical extracts: vitamin D3, vitamin B12, chromium picolinate, white mulberry leaf, and fenugreek seed extracts. The source document reports administration of resM versus matched placebo but does not provide additional details such as dosing schedule or capsule count in the text provided here.
The primary outcome was the absolute change in body weight at the final scheduled weekly assessment (Week 7). Secondary endpoints included body-mass index (BMI); fasting insulin, hemoglobin A1c (HbA1c), and HOMA-IR; serum active GLP-1; strain-specific stool quantitative PCR for L. plantarum RSB11; food cravings measured with the Food Craving Questionnaire–Trait–reduced; depressive symptoms measured with the PHQ-9; routine safety laboratory measures; and adverse-event surveillance.
Between-group differences were evaluated using independent-samples t-tests and baseline-adjusted ANCOVA. Within-group changes were evaluated using paired tests. The source reports statistical significance for some within-arm changes (for example, food-craving reductions with p<0.001) but full statistical tables, confidence intervals, and effect sizes beyond those explicitly stated in the abstract are not reported in the provided text.
Over the 8-week intervention, participants randomized to resM experienced a mean weight decrease of 2.6 kg (approximately 3.0%), whereas participants randomized to placebo experienced a mean weight increase of 0.5 kg (approximately 0.6%). Food-craving scores declined by 15.1 points within the resM arm over the 8 weeks (p<0.001). Depressive symptom scores likewise decreased within the resM group during the study period. Metabolic laboratory endpoints are listed among secondary outcomes (fasting insulin, HbA1c, HOMA-IR), but the provided summary does not report specific numeric results for these measures.
Treatment with resM was associated with an approximately two-fold increase in circulating active GLP-1 during the intervention; the increase was larger in the resM group than in placebo. Additionally, serum GLP-1 levels correlated with detection of L. plantarum RSB11 in stool samples measured by strain-specific qPCR among participants in the resM arm. These findings suggest an association between oral administration of the heat-inactivated RSB11-containing formulation and endogenous GLP-1 responses, as well as a measurable stool signal for the RSB11 strain after administration. The source does not provide numerical GLP-1 concentrations or correlation coefficients in the abstracted text.
No serious adverse events were reported in either group. Safety laboratory values remained within reference ranges over the study period. Gastrointestinal symptoms were reported more frequently with placebo than with resM according to the supplied summary. The report indicates routine adverse-event surveillance was performed, but the provided text does not enumerate specific non-serious adverse events or their frequencies beyond the gastrointestinal symptom observation.
The authors note the need for larger and longer-duration trials to confirm the persistence and generalizability of the findings. The trial was a short-duration (8-week) study in 80 participants and was conducted remotely; these design elements may limit generalizability and assessment of long-term efficacy and safety. Relevant competing interests are disclosed: Resbiotic Nutrition, Inc. provided financial and/or in-kind support, Able Biolabs provided contract research services, and several authors are employees, consultants, shareholders, officers, or inventors affiliated with Resbiotic Nutrition, Inc. and/or Able Biolabs with interests related to resM or RSB11. The study received ethical approval from Sterling Institutional Review Board and was registered on ClinicalTrials.gov.
In this randomized, placebo-controlled study, oral administration of resM over 8 weeks produced clinically meaningful short-term weight loss within the intervention arm and compared with placebo, reduced food cravings and depressive symptom scores, and was associated with an approximately two-fold rise in circulating active GLP-1 with stool detection of the RSB11 strain correlating with GLP-1 levels. Safety signals in the provided summary were reassuring over the 8-week period, with no serious adverse events and routine labs remaining within reference ranges. The investigators conclude that larger, longer-duration trials are required to establish the durability, mechanisms, and generalizability of these results.
Note: This report summarizes findings as presented in the source preprint. The preprint has not been peer reviewed and should not be used to guide clinical practice without confirmatory published evidence.